Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.03
$0.65
$0.03
$0.59
$857K0.226.48 million shsN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$12.08
-7.3%
$13.29
$7.94
$19.11
$1.09B1.721.01 million shs1.08 million shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$5.99
-1.5%
$5.98
$3.75
$9.40
$27.42M1.5325,928 shs28,442 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00%0.00%0.00%0.00%-16.05%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+10.61%+5.51%-3.12%+44.30%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.00%-1.94%+15.81%+21.36%+19.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.03
$0.65
$0.03
$0.59
$857K0.226.48 million shsN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$12.08
-7.3%
$13.29
$7.94
$19.11
$1.09B1.721.01 million shs1.08 million shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$5.99
-1.5%
$5.98
$3.75
$9.40
$27.42M1.5325,928 shs28,442 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00%0.00%0.00%0.00%-16.05%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+10.61%+5.51%-3.12%+44.30%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.00%-1.94%+15.81%+21.36%+19.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00
N/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$31.80163.25% Upside
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.00
Hold$6.000.17% Upside

Current Analyst Ratings Breakdown

Latest HBIO, EYPT, and AXDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Lower Price TargetOutperform$39.00 ➝ $37.00
4/21/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingSell (D-)
3/27/2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Reiterated RatingSell (D-)
(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$11.70M0.07N/AN/A($1.37) per share-0.02
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$31.37M32.29N/AN/A$3.70 per share3.26
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$86.55M0.31$11.52 per share0.52$3.07 per share1.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$2.34N/AN/AN/A-471.83%N/A-191.66%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$231.96M-$3.50N/AN/AN/A-3,566.63%-110.54%-90.15%8/5/2026 (Estimated)
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$56.70M-$2.17N/AN/AN/A-11.44%-25.78%-4.37%8/10/2026 (Estimated)

Latest HBIO, EYPT, and AXDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$0.62-$0.33+$0.29-$0.77$21.20 million$20.76 million
5/6/2026Q1 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
1.50
1.34
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
6.66
6.63
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.60
1.99
1.06

Institutional Ownership

CompanyInstitutional Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17.14%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%

Insider Ownership

CompanyInsider Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
43.60%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
5.13%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
20.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
22025.21 million14.13 millionNo Data
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12083.84 million79.54 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4904.51 million3.59 millionOptionable

Recent News About These Companies

HBIO Q1 2026 Earnings Transcript
Harvard Bioscience: Q1 Earnings Snapshot
Harvard Bioscience, Inc. Q4 2025 Earnings Call Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

Accelerate Diagnostics stock logo

Accelerate Diagnostics NASDAQ:AXDX

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$12.08 -0.95 (-7.29%)
Closing price 04:00 PM Eastern
Extended Trading
$12.21 +0.13 (+1.11%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$5.99 -0.09 (-1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$5.98 -0.01 (-0.17%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.